ACT	adoptive cell therapy;
AE	adverse events;
ALK	Anaplastic lymphoma kinase;
BAD	BCL-2 antagonist of cell death
BRAF	v-raf murine sarcoma viral oncogene homolog B1;
BRAF	inhibitor (BRAFi)
CAR-T	chimeric antigen receptor T cells;
CCND1	cyclin D1;
CDK4	cyclin-dependent kinase 4;
CDKN2A	cyclin-dependent kinase inhibitor 2 receptor;
ChT	chemotherapy;
CSD	cumulative sun damage;
CTLA-4	cytotoxic T-lymphocyte–associated antigen 4;
CTNNB1	Catenin Beta 1;
cuSCC	cutaneous squamous cell carcinoma;
DVL	dishevelled;
ERK	extracellular signal-related kinase;
FAMMM	familial atypical multiple mole-melanoma;
FDA	US Food and Drug Administration;
FRZD	Frizzled receptors;
GEP	gene expression profiles;
GPCR	G-protein-coupled receptors;
GSK3β	glycogen synthase kinase 3β;
GTPase	guanosine triphosphatases;
HRAS	v-Ha-ras Harvey rat sarcoma viral oncogene homolog;
ICI	immune checkpoint inhibitor;
IFNG	interferon-gamma;
IL	interleukin;
iNOS	inducible nitric oxide synthase;
JNK	c-Jun N-terminal kinases;
KRAS	v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog;
LEF	lymphoid enhanced transcription factor;
LRP	lipoprotein receptor;
MAPK	mitogen-activated protein kinase;
MAP2K1	mitogen-activated protein kinase kinase 1;
MAP3K1	mitogen-activated protein kinase kinase kinase 1;
MC1R	melanocortin 1 receptor;
MDM2	Mouse double minute 2 homolog;
MEK	inhibitors (MEKi)
MITF	microphthalmia-associated transcription factor;
mTOR	mammalian target of rapamycin;
NBD	NEMO-binding domain;
NF1	neurofibromin 1;
NFκB	nuclear factor-kappaB;
NTRK	Neurotrophic Tyrosine Receptor Kinase;
NRAS	neuroblastoma ras viral oncogene homolog;
ORR	overall response rate;
OS	overall survival;
PD1	programmed cell death-1;
PD-L1	programmed cell death ligand-1;
PI3K	phosphatidylinositol-3-kinase;
PIP2	phosphatidylinositol-4,5-diphosphate
PIP3	phosphatidylinositol-3,4,5-trisphosphate
PTEN	phosphatase and tensin homolog;
RTK	receptor tyrosine kinase;
SF3B1	Splicing Factor 3b Subunit 1;
TCR-T	T-cell receptor– engineered T cells;
TERT	Telomerase Reverse Transcriptase;
TILS	Tumor-infiltrating lymphocytes;
TCF	T-cell transcription factor;
TCGA	The Cancer Genome Atlas
TNF	tumor necrosis factor;
TRAE	treatment-related adverse event
TRK	tropomyosin receptor kinases;
UV	ultraviolet;
WHO	World Health Organization